Antibody-drug conjugates in solid tumors; new strategy for cancer therapy

Abstract Antibody-drug conjugates (ADCs) have emerged as a novel class of anticancer treatment. ADCs are composed of three parts: a monoclonal antibody, a linker and a payload. A monoclonal antibody binds to the specific antigen present at the cancer cells, allowing selective delivery of the cytotox...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of clinical oncology 2024-05, Vol.54 (8), p.837-846
Main Authors: Takakura, Toshiaki, Shimizu, Toshio, Yamamoto, Nobuyuki
Format: Article
Language:English
Subjects:
Review (Invited)
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Antibody-drug conjugates (ADCs) have emerged as a novel class of anticancer treatment. ADCs are composed of three parts: a monoclonal antibody, a linker and a payload. A monoclonal antibody binds to the specific antigen present at the cancer cells, allowing selective delivery of the cytotoxic agents to the tumor site. Several ADCs are approved by the US Food and Drug Administration for the treatment of hematologic cancers and solid tumors with clinically meaningful survival benefit. However, the development of ADCs faces a lot of challenges and there is a need to get better understanding of ADCs in order to improve patient outcomes. Here, we briefly discuss the structure and mechanism of ADCs, as well as the clinical data of current approved ADCs in solid tumors. This article reviews recent trends of ADCs’ drug development against solid tumors. The ability to deliver payloads selectively to targeting cancer cells potentially enable strengthen efficacy and improve safety profiles.
ISSN:1465-3621
0368-2811
1465-3621
DOI:10.1093/jjco/hyae054